Efficacy of adoptive cellular therapy with naive rich T cell on recurrence after curative radiofrequency ablation for primary hepatocellular carcinoma (Phase 2 study)
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000003861
- Lead Sponsor
- Kyoto Prefectural University of Medicine, Division of Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Not provided
1. Patient who has uncontrollable severe infectional disease. 2. Patient who has allergic disease or autoimmune disease requiring treatment. 3. Patient who is associated with malignant hypertension, severe congestive heart disease, unsatble angina, myocardial infarction within 6 months prio to registration, severe pulmonary fibrosis and active interstitial pneumonia. 4. Patient who cannot undergo enhanced CT scan or MRI due to some reason such as allergy for contrast media or renal dysfunction. 5. Patient who has uncontrollable associated cancer. 6.Patient with severe drug allergy. 7.Patient with severe psychiatric disorder. 8.In pregnancy or lactation. 9. Patient with HIV or HTLV-1 infection. 10.Patient who is inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Three-year recurrence-free survival
- Secondary Outcome Measures
Name Time Method overall survival, disease-specific survival, immunological response, safety